| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 2123200 | European Journal of Cancer | 2011 | 5 Pages |
Abstract
The contemporary management of metastatic castration-resistant prostate cancer (mCRPC) is evolving dramatically. Understanding the biology of this disease, positive phase III studies and approvals for 4 novel agents in the US in 2010 and shortly in Europe have dramatically changed the therapeutic landscape.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
